Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.50 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712427 | 1.00 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL574174 | 0.99 | KMT2A (0.51) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL2553480 | 0.97 | KMT2A (0.49) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL3535605 | 0.93 | MERTK (0.48) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL22860490 | 0.88 | MERTK (0.45) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL29507782 | 0.88 | MERTK (0.45) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16416502 | 0.86 | MERTK (0.41) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4154549 | 0.86 | MERTK (0.41) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL19857398 | 0.86 | MAPK8 (0.45) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL30597066 | 0.85 | MERTK (0.41) | KMT2AMEN1GABBR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| CN-114394966-A | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | KMT2A 298/4885MEN1 1336/4885GABBR2 4636/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | KMT2A 292/4885MEN1 1282/4885GABBR2 4688/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | KMT2A 298/4885MEN1 1336/4885GABBR2 4636/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | KMT2A 298/4885MEN1 1336/4885GABBR2 4636/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | KMT2A 298/4885MEN1 1336/4885GABBR2 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.